Thymosin Alpha-1 dosage across clinical studies

Hepatitis, sepsis and study duration

Thymosin Alpha-1 protocols changed with the clinical question. Hepatitis studies commonly continued for months; the sepsis trials tested a brief course during critical illness. A reader searching for a single dosage encounters several different experiments.

I’m reluctant to detach an amount from the people who received it. The clinical review records a hepatitis regimen of 1.6 mg subcutaneously twice weekly. That describes administration under the skin in a clinical setting. It supplies no personal dose recommendation.

All amounts and schedules on this page are historical study records. Choosing treatment requires an individual clinical assessment. An entry in a trial protocol cannot do that assessment.

Thymosin alpha 1 dosage

The comprehensive review describes single subcutaneous doses ranging from 0.8 to 6.4 mg and multiple-dose regimens of 1.6–16 mg over five to seven days. Those ranges combine research settings; they are not an invitation to choose a point between the endpoints.

The accompanying context makes those figures useful to me: what illness was treated, what else was given, and what outcome was followed. The 2024 safety review adds information about tolerability, while the individual efficacy studies answer narrower disease questions.

The most useful comparison remains the treatment groups within a study. A larger amount in another disease cannot explain away an unfavourable trial result.

A licensed prescriber orders each thymosin alpha 1 injection

Essentially every clinical trial used the thymosin alpha 1 injection route of subcutaneous administration ^[4]. The sepsis trials clustered around 1.6 mg every 12 hours for five to seven days: ETASS used 1.6 mg every 12 hours for 5 days, then once daily for 2 days ^[2], while the phase-3 TESTS protocol used 1.6 mg every 12 hours for 7 days ^[3]. COVID-19 cohort studies generally used 1.6 mg subcutaneously daily ^[6]. Beyond clinical trials, the peptide has also been administered in vitro and ex vivo in mechanistic studies, and intraperitoneally in mouse models ^[5][8] — but the human route of record is subcutaneous injection.

Which raises the question this page keeps bumping into: every regimen above was run by a clinician, so who writes the script? In the U.S., thymalfasin lacks FDA drug approval; prescription care still starts with a licensed prescriber. With Promise Peptides (mypromise.com), thymosin alpha-1 prescription care is now open: a licensed U.S. clinician checks each person’s case before deciding whether to prescribe. A declined request means no prescription. Only people in the U.S. can use this care, and the treatment choices are different from state to state. The compounded preparation has no FDA approval. The clinical decision comes before the prescription. The prescriber sets the protocol — same as in every trial quoted above.

Blood concentrations after injection

In healthy volunteers, blood concentrations peaked about 1–2 hours after subcutaneous injection, the elimination half-life was approximately two hours, and concentrations returned towards baseline within about 24 hours, as summarised in the clinical review. These measurements follow the peptide through the body.

The blood curve tells me about clearance; a promised time to feel better remains out of reach. An immune-cell response and a clinical outcome are separate observations. The same pharmacokinetic facts can sit beside different results in hepatitis, sepsis and COVID-19.

Longer observation

Some cancer research continued weekly injections for up to 12 months alongside other treatment, according to the clinical review. That duration records how a combination was studied. It does not establish that a longer course improves outcomes.

The safety cautions include pregnancy, lactation, autoimmune disease and solid-organ transplantation. Those questions remain relevant however familiar an amount looks in print. A personal dose decision requires medical history that a literature table cannot supply.